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Systemic frequencies of T helper 
1 and T helper 17 cells in patients 
with age-related macular 
degeneration: A case-control study
Amardeep Singh1,2, Yousif Subhi  1,3, Marie Krogh Nielsen1,3, Mads Krüger Falk1, Sara Maj 
Hyldig Matzen4, Finn Sellebjerg3,5 & Torben Lykke Sørensen1,3
Age-related macular degeneration (AMD) is a degenerative disease of the retina and a leading cause of 
irreversible vision loss. We investigated the systemic differences in the frequency of T helper (Th) 1 and 
Th17 cells in patients with non-exudative and exudative AMD and compared to age-matched controls. 
Flow cytometry was used to determine the systemic frequency of Th1 (CD4+CXCR3+IL12RB2+) and 
Th17 (CD4+CCR6+IL23R+) cells, and percentage of CD4+ T-cells expressing CXCR3, IL12RB2, CCR6, 
IL23R, and co-expressing CXCR3 and CCR6. The frequency of Th1 cells and CXCR3+ CD4+ T-cells was 
lower in patients with exudative AMD. A significant age-dependent decrement in Th1 was observed in 
controls, but not in non-exudative or exudative AMD. This may be related to the CXCR3+ CD4+ T-cells, 
which showed similar pattern in controls, but not in non-exudative or exudative AMD. No significant 
group differences were observed for the frequency of Th17 cells. Correlation networks found several 
differences between controls and AMD. These data suggests the involvement of the adaptive immune 
system in AMD and supports the notion of AMD as a systemic disease. Our observations warrant further 
investigation into the role of the adaptive immune system in the pathogenesis of AMD.
Age-related macular degeneration (AMD) is a degenerative disease of the photoreceptor cells, retinal pigment 
epithelium (RPE), and Bruch’s membrane in the macular region of the retina1. It is the most common cause of 
irreversible vision loss in the elderly and significantly impacts quality of life2–4. Early stages are usually asymp-
tomatic and characterized by the presence of drusen, which are extracellular accumulations in proximity to the 
RPE. In the later stages, atrophy of the outer retina leads to gradual and irreversible vision loss. Rapid visual loss 
often ensues when choroidal vessels proliferate and break through the Bruch’s membrane to enter the sub-RPE or 
the subretinal space resulting in hemorrhage, exudation, or edema in the macula. This stage is commonly referred 
to as the neovascular or exudative AMD.
Despite recent advancements in the understanding of the pathogenesis of AMD, the underlying mechanisms 
are still incompletely understood. The immune system is believed to play an important role and it has been pro-
posed that an imbalance between tissue stress (e.g. due to oxidative changes) and para-inflammatory responses 
(e.g. due to genetic mutations) is central to the development of AMD5, 6. Although AMD exclusively affects the 
posterior pole of the eye, immunological changes in the systemic circulation have been reported in patients with 
AMD, strongly indicating a systemic component in AMD7–15.
In understanding the pathogenesis of AMD, the attention has primarily been directed towards the innate 
immune system. However, there is some evidence to suggest that the adaptive immune system may also be 
involved to some degree. For instance, autoantibodies have been found in blood of patients with AMD16, 17 and 
CD8+ T-cells have been identified in the choroid of donated human eyes affected by AMD18, 19. Further evi-
dence for involvement of the adaptive immune system arises from the observation that major histocompatibility 
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complex class (MHC) II molecules are present on RPE and enhanced on activated microglia enabling antigen 
presentation to T cells potentially recruited to the eye20, 21. The RPE, choroid and retina of aged mice over-express 
several genes related to T-cells and their chemotaxis, antigen presentation, and adhesion22, 23. Collectively, these 
findings suggest a potential role of the adaptive immune system, in particular the T-lymphocytes, in the patho-
genesis of AMD.
Activated CD4+ T cells can be differentiated based on production of signature cytokines into T helper (Th1), 
Th2, Th17 and regulatory (Treg) subsets24. The Th1 and Th17 subsets secrete pro-inflammatory cytokines and are 
also involved in neurodegenerative and neovascular processes25–28. The Th1 and Th17 subsets can be recognized 
and separated by their expression of the surface proteins CXCR3 and IL12RB2 or CCR6 and IL23R, respectively. 
To the best of our knowledge, the occurrence of these pro-inflammatory T cell subsets has not been investigated 
in AMD. The purpose of this study was to investigate any potential differences in the frequency of Th1 and Th17 
cells in the systemic circulation of patients with different subgroups of AMD and controls. Moreover, we explored 
potential differences in the expression of the individual surface proteins, IL12RB2, IL23R, CCR6, and CXCR3. 
Finally, we assessed the co-expression of CXCR3 and CCR6 on CD4+ cells since we have previously found differ-
ences in the expression of these proteins in patients with multiple sclerosis29.
Methods
This prospective case-control study was approved by the Regional Committee of Ethics in Research of the Region 
of Zealand (Journal No. SJ-142). Verbal and written consent was obtained from all participants before inclusion. 
We followed the ethical principles for medical research stated in the Declaration of Helsinki.
Study participants, clinical diagnosis, and medical data. Participants were consecutively recruited 
from our Department of Ophthalmology at Zealand University Hospital, Roskilde, Denmark. We recruited 
patients with exudative and non-exudative AMD from our outpatient retinal program. Healthy relatives of the 
patients were invited to participate as age-matched control individuals. This was an intentional strategy to better 
match the control group. Since this was a hypothesis-driven study, our aim for the number of participants was 
based on our previous experience with studies of systemic lymphocytes in patients with AMD rather than a power 
calculation, which is at least 20 individuals in each group9, 12, 30. We thus recruited at least 20 individuals in each 
group and stopped including further participants after recruiting a total of 90.
Retinal diagnosis was made by trained ophthalmologists using bilateral ophthalmoscopic fundus exam-
ination using a 90 diopter lens in mydriasis, digital color fundus photography (Carl Zeiss, Jena, Germany), 
Spectral-Domain Optical Coherence Tomography and fundus autofluorescence imaging (Spectralis HRA-OCT, 
SLO Heidelberg Engineering, Heidelberg, Germany). Participants suspected of having exudative AMD were 
also subjected to fluorescein and indocyanine green angiography to confirm diagnosis. Participants were cate-
gorized into subgroups of AMD according to the Clinical Age-Related Maculopathy Staging (CARMS) system31. 
Participants were classified as having non-exudative AMD (equivalent to CARMS score 2–4) if they exhibited 
signs of pigment abnormalities associated with age-related maculopathy, approximately ≥10 small drusen or any 
intermediate drusen, drusenoid retinal pigment epithelial detachment or geographic atrophy. Participants were 
classified as having exudative AMD (equivalent to CARMS score 5) if they had signs of neovascular AMD, includ-
ing nondrusenoid pigment epithelial detachments, serous retinal detachments, choroidal neovascular membrane 
with subretinal or sub-RPE hemorrhages, or subretinal fibrosis. Non-AMD controls (equivalent to CARMS score 
1) had normal maculae without drusen or fewer than 10 small drusen without pigment abnormalities. Both eyes 
were examined, and if the CARMS stages differed between the two eyes, the higher CARMS stage (5 being the 
highest) was chosen.
All participants were subjected to a structured standardized interview where medical conditions and cur-
rent medication use was recorded. Based on their smoking habits, participants were categorized as either never 
smokers (less than 100 cigarettes during lifetime), ex-smokers (more than 100 cigarettes during lifetime but not 
within the last 12 months), or current smokers (which included those who reported quitting within the last 12 
months)32. Height and weight were measured and used to calculate the body mass index (BMI). The participants 
were categorized as being either physically active or inactive based on a single-sentence questionnaire validated 
for observational studies4, 33. Alcohol use was noted as units (=12 g ethanol) per week.
Participant eligibility. Participants were not included if they reported being ill within the last five days, had 
a history of any form of ongoing cancer, or systemic inflammatory or autoimmune conditions. Participants were 
also not included if they were receiving immune-modulating therapy, had received anti-vascular endothelial 
growth factor (VEGF) with Ranibizumab (Lucentis®, Genentech, South San Francisco, CA, USA) or Aflibercept 
(Eylea®, Bayer, Leverkusen, Germany) within the last 30 or 60 days, respectively, or were affected by any eye 
condition that hampered confident grading of the patient’s maculae. No participant had received other forms of 
intravitreal therapy, e.g. bevacizumab or lampalizumab.
Venous blood was obtained in a 3.5 ml evacuated gel tube containing lithium-heparin to measure the systemic 
C-reactive protein concentration. Individuals with C-reactive protein concentrations higher than 15 mg/l (∼99th 
percentile of the general population) were excluded to avoid interference with undiagnosed infectious, inflam-
matory or malignant conditions34.
Leukocyte preparation and flow cytometric analysis. Fresh blood (3 ml) from the antecubital vein 
was obtained from all participants in tubes containing ethylenediamine-tetraacetic acid coagulant, and prepa-
ration for flow cytometric analysis was begun within 4 hours. Blood sampling was performed prior to any fluo-
rescein and indocyanine angiography to avoid interference35. The volume of blood used for each participant was 
equivalent to 5 × 105 white blood cells and calculated using a white blood cell count in a hematology analyzer 
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(Sysmex KX-21NTM, Sysmex Corporation, Kobe, Japan). The red blood cells were lysed by adding 10% red blood 
cell lysis buffer (Nordic Biosite AB, Täby, Sweden) to the entire blood sample for 10 minutes in the dark at room 
temperature. The cells were washed three times and after each wash centrifuged for 5 minutes at 500 G and finally 
resuspended in isotonic buffer (IsoFlow Sheath Fluid, Beckman Coulter, Inc, Brea, CA, USA). The following 
monoclonal anti-human antibodies were applied to the sample: Allophycocyanin-H7 CD4, Clone RPA-T4, IgG1 
(catalog number 560158, BD Pharmingen, Franklin Lakes, NJ, USA); PE-CY7 CXCR3/CD183-PE-CY7 Clone 
1C6 IgG1 (catalog number 560831, BD Pharmingen); Allophycocyanin IL12R-B2 Clone 305719 IgG1 (catalog 
number FAB1959A, R&D Systems, Inc, Minneapolis, MN, USA); FITC CCR6 Clone G034E3 IgG2B (catalog 
number 353412, Biolegend, San Diego, CA, USA); PE IL23R Clone 218213 IgG2B (catalog number FAB14001P, 
R&D Systems Inc). Corresponding fluorochrome-matched negative isotype controls were used in a separate tube 
and set at 1% (APC-H7 Mouse IgG1, k isotype control, catalog number 560167, BD Pharmingen; PE-Cy7 Mouse 
IgG1 k isotype control, catalog number 557872, BD Pharmingen; APC Mouse IgG1 isotype control, catalog num-
ber IC002A R&D Systems Inc; FITC Mouse IgG2b, k isotype control, catalog number 400310, Biolegend; Mouse 
IgG2b isotype control, catalog number IC0041P, R&D Systems Inc). After incubation at room temperature in 
the dark as recommended by the respective manufacturers, the cells were washed and resuspended in 300 µl of 
isotonic buffer. The stained cells (n = 100 000) were analyzed using BD FACSCANTO II flow cytometry (BD 
Biosciences, Franklin Lakes, NJ, USA) and Kaluza Software (v. 1.5.20365.16139, Beckman Coulter Inc., Pasadena, 
CA, USA).
We plotted forward scatter area vs. height to identify singlets. Then, lymphocytes were gated using forward/
side scatter plot. CD4+ cells were then isolated and the percentage of CD4+ cells expressing both CXCR3 and 
IL12RB2 (representing Th1 cells) and CCR6 and IL23R (representing Th17 cells) were assessed using two differ-
ent dot-plot diagrams (Fig. 1). In order to look for potential differences in the individual surface proteins, we also 
examined the expression of IL12RB2, IL23R, CCR6, CXCR3. In addition, the co-expression of CXCR3 and CCR6 
on CD4+ cells was quantified.
Data analyses and statistics. First, demographic and clinical characteristics between groups were com-
pared. We then explored differences between groups in the frequency of Th1 and Th17 cells, and the percent-
age of CD4+ T cells expressing the individual proteins. As aging introduces changes in the T-cell population, 
we performed correlation analyses between advancing age and frequencies of all CD4+ T cell subsets studied. 
Finally, we explored correlations between the CD4+ T cell subsets using group-specific correlation networks. 
We analyzed all data using SPSS 23 (IBM, Armonk, NY, USA). Data with normal distribution are presented 
using mean and standard deviation (SD), compared using the one-way analysis of variance (ANOVA) and the 
independent samples t-test, and correlated using Pearson’s correlation. As the median Th1/Th17 ratio and fre-
quency of CD4+CXCR3+CCR6+ cells did not fit into normal distribution, these data are presented using median 
and interquartile range (IQR), compared using the Kruskal-Wallis’ one-way analysis of variance by ranks and 
the Mann-Whitney U test, and correlated using Spearman’s correlation. Categorical variables are presented in 
numbers and percentages, and compared using the χ2-test or Fisher’s Exact test when categories were <10. We 
consider a P-value below 0.05 as a sign of statistical significance.
Results
Participant characteristics. Of the 90 participants recruited in total, 32 were patients with exudative 
AMD, 26 were patients with non-exudative AMD (3 with CARMS 2, 9 with CARMS 3, and 14 with CARMS 4), 
and 32 were healthy control individuals. We excluded four participants (two patients with exudative AMD, one 
patient with non-exudative AMD, and one control individual) due to presumed ongoing acute immune response 
reflected by C-reactive protein concentrations higher than 15 mg/l. Another two participants, one control individ-
ual and one patient with non-exudative AMD, were excluded due to onset of severe allergic rhinitis and asthma 
exacerbation, respectively, on the day of recruitment. Participant characteristics of the 84 participants included 
for the analyses are summarized in Table 1. The groups did not differ significantly in demographic, lifestyle, and 
medical factors.
Group differences in CD4+ T-cells’ surface protein expression and subtype. We quantified the per-
centage of CD4+ cells co-expressing CXCR3 and IL12RB2 to study the frequency of Th1 cells in blood (Table 2). 
Lower frequency of Th1 cells was observed among patients with exudative AMD (p = 0.049, ANOVA; p = 0.024, 
independent samples t-test between control and exudative AMD). We quantified the percentage of CD4+ cells 
co-expressing CCR6 and IL23R to study the frequency of Th17 cells in blood, and found no difference between the 
three groups (p = 0.351, ANOVA). The Th17/Th1 ratio was similar in the three groups (p = 0.973, Kruskal-Wallis’ 
test). No significant differences were found in the expression of IL12RB2, IL23R, or CCR6 on CD4+ T-cells. The 
expression of CD4+ T-cells expressing CXCR3 was significantly lower in patients with AMD (p = 0.025, ANOVA; 
p = 0.014, independent samples t-test between control and exudative AMD; p = 0.064, independent samples t-test 
between control and non-exudative AMD). The co-expression of CXCR3 and CCR6 on CD4+ T-cells was also 
lower in patients with AMD (p = 0.028, Kruskal Wallis’ test; p = 0.016, Mann-Whitney U-test between control 
and exudative AMD; p = 0.052, Mann-Whitney U-test between control and non-exudative AMD).
Impact of aging. The range of age was similar between the three groups: 59 to 88 years in healthy controls, 
58 to 96 in patients with non-exudative AMD, and 59 to 87 in patients with exudative AMD. In healthy controls, 
increasing age correlated with decreasing frequency of Th1 cells (ρ = −0.51, p = 0.005, Pearson’s correlation) and 
percentage of CD4+ T cells with co-expression of CXCR3+ and CCR6+ (ρ = −0.43, p = 0.022, Spearman’s corre-
lation); and increasing age correlated with increasing Th17/Th1 ratio (ρ =  + 0.64, p = 0.022, Spearman’s correla-
tion) and percentage of CD4+ T-cells expressing CXCR3(ρ =  + 0.45, p = 0.017, Pearson’s correlation) (Table 3). 
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These correlations were absent in patients with non-exudative and exudative AMD, in which expression of none 
of the surface proteins studied correlated with age.
Group-specific correlation networks. The relationships between Th1, Th17, and expression of the 
individual cell surface proteins on CD4+ T-cells were investigated using group-specific correlation networks 
(Fig. 2). These networks revealed several differences in how the frequencies correlate with each other between 
the different groups, suggesting that a more complex systemic immune dysfunction in the adaptive immune 
system may be present in patients with AMD. Compared to control individuals, patients with exudative AMD 
lacked correlations of CD4+IL23R+ T-cells with Th1, CD4+CXCR3+, and CD4+CXCR3+CCR6+; and of 
Figure 1. Gating strategies for identifying T helper 1 (Th1) and 17 (Th17) cells using Kaluza Software. (a) 
We first identified CD4+ T-cells by first identifying singlets (using forward height vs. area scatter), then 
lymphocytes (using forward vs. side scatter), and then the CD4+ lymphocyte population. (b) Th1 cells are 
CD4+CXCR3+IL12RB2+, so we first gated CD4+ and identified CXCR3+ cells, which we then gated to identify 
the IL2RB2+ cells. We used negative isotype control at 1% to distinguish positive populations from non-specific 
background signals. (c) Th17 cells are CD4+CCR6+IL23R+, so we first gated CD4+ and identified CCR6+ cells, 
which we then gated to identify the IL23R+ cells. We used negative isotype control at 1% to distinguish positive 
populations from non-specific background signals.
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CD4+CXCR3+ with Th17 cells. Instead, other correlations were present of CD4+CCR6+ with Th17 cells, Th17/
Th1-ratio, and CD4+CXCR3+CCR6+ cells; and of Th17/Th1-ratio with Th17 and CD4+IL23R+ cells. Patients with 
non-exudative AMD had features of both control individuals and patients with exudative AMD, i.e. correlations 
of CD4+IL23R+ with Th1 and CD4+CXCR3+CCR6+ cells; of CD4+CCR6+ cells with Th17 cells, Th17/Th1-ratio, 
and CD4+CXCR3+CCR6+ cells; and of Th17/Th1-ratio with Th17 and CD4+IL23R+ cells.
Discussion
The adaptive immune system is composed of highly specialized cells, T- and B-cells, designated to eliminate 
or prevent pathogen growth. T-helper cells are central players in adaptive immunity as they activate B-cells to 
secrete antibodies, macrophages to destroy ingested microbes, and cytotoxic T-cells to kill infected target cells33. 
T-helper cells, which differentiate from naïve CD4+ T-cells, may further differentiate into interferon-gamma 
(IFN-γ)-secreting Th1-cells (which support clearance of intracellular pathogens) under the influence of IFN-γ 
Controls (n = 30) Non-exudative AMD (n = 24) Exudative AMD (n = 30) P-value
Age, years, mean (SD) 72.5 (6.8) 76.2 (8.7) 76.9 (7.6) 0.066
Gender, n (%) 0.166
 Female 17 (57) 19 (79) 17 (57)
 Male 13 (43) 5 (21) 13 (43)
Smoking history, n (%) 0.513
 Never 13 (43) 8 (33) 10 (35)
 Ex-smoker 11 (37) 10 (42) 16 (55)
 Current smoker 6 (20) 6 (25) 3 (10)
BMI, kg · m−2, mean (SD) 26.7 (3.0) 25.9 (4.5) 24.6 (2.9) 0.054
Physically active, n (%) 15 (50) 11 (46) 13 (45) 0.916
Alcohol use, units/week, median (IQR) 3 (0 to 10) 2 (0 to 9) 3 (0 to 6) 0.828
Co-morbidities, n (%)
 Dyslipidemia 7 (23) 8 (33) 6 (20) 0.442
 Hypertension 15 (50) 13 (54) 17 (57) 0.848
 Other CVDs 7 (23) 8 (33) 6 (20) 0.540
C-reactive protein 0.166
<2.9 mg · L−1l, n (%) 20 (67) 18 (75) 18 (60)
2.9–7.9 mg · L−1, n (%) 7 (23) 6 (25) 12 (40)
8.0–14.9 mg · L−1, n (%) 3 (10) 0 (0) 0 (0)
Table 1. Demographic, lifestyle, and medical characteristics of included study participants. Abbreviations: 
n = number; AMD = age-related macular degeneration; SD = standard deviation; BMI = body mass index; 
CVDs = cardiovascular diseases. Missing data: smoking history is missing for one participant with exudative 
AMD, body mass index is missing for two participants with non-exudative AMD, and physical activity is 
missing for one participant with exudative AMD. P-values are calculated using analysis of variance (ANOVA) 
for age and body mass index; Kruskal-Wallis’ test for alcohol consumption, χ2-test for hypertension and 





AMD (n = 24)
Exudative 
AMD (n = 30)
P-value 
(group)




Th1 (CD4+CXCR3+IL12RB2+), mean (SD) 6.1 (4.8) 4.2 (3.3) 3.7 (2.2) 0.031a 0.098b 0.016b
Th17 (CD4+CCR6+IL23R+), mean (SD) 9.2 (5.8) 8.0 (7.1) 6.3 (5.5) 0.181a — —
Th17/Th1 ratio, median (IQR) 1.6 (1.0 to 2.2) 1.5 (0.9 to 2.5) 1.3 (0.7 to 2.7) 0.631
c — —
CD4+IL12RB2+, mean (SD) 38.9 (8.4) 38.5 (8.8) 37.5 (5.3) 0.780a — —
CD4+IL23R+, mean (SD) 24.9 (13.4) 24.4 (15.3) 18.7 (13.1) 0.173a — —
CD4+CXCR3+, mean (SD) 13.9 (10.7) 9.4 (7.0) 8.2 (5.1) 0.019a 0.066b 0.012b
CD4+CCR6+, mean (SD) 28.8 (9.8) 21.1 (11.9) 22.9 (10.6) 0.024a 0.015b 0.030b
CD4+CXCR3+CCR6+, median (IQR) 4.1 (2.4 to 8.6) 1.6 (1.1 to 4.7) 2.2 (1.4 to 4.0) 0.009
c 0.007d 0.014d
Table 2. CD4+ T-cell surface protein expression in patients with non-exudative age-related macular 
degeneration (AMD), patients with exudative AMD, and control individuals. Abbreviations: n = number; 
AMD = age-related macular degeneration; Th1 = T helper 1; Th17 = T helper 17; SD = standard deviation. 
Groups are compared using: aanalysis of variance (ANOVA); bindependent samples t-test; cKruskal-Wallis test; 
dMann-Whitney U-test. Cell populations with significant differences are greyed out.
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and interleukin (IL)-12. In a mouse model, ocular injection of carboxyethylpyrrole, a lipid peroxidation prod-
uct associated with AMD in humans and AMD-like pathology in mice, resulted in a T-cell dependent adaptive 
immune response with Th1 differentiation, or IFN-γ production in general, seemingly playing an essential role 
in the process36.
We observed that patients with exudative AMD had lower frequency of CD4+CXCR3+ IL12RB2+ (Th1) 
cells compared to control individuals. Although generally considered to be pro-inflammatory, the exact role of 
Th1-secreted IFN-γ is unclear. It may be pro-inflammatory due to secretion of pro-inflammatory cytokines and 
chemokines which recruit monocytes/macrophages and T-cells, or anti-inflammatory due to upregulation of 
anti-inflammatory factors and inhibition of immune cells related to the autoimmune response37. The immune 
system and in particular the T-cell compartment undergoes age-related changes, a phenomenon known as 
Controls (n = 30) Non-exudative AMD (n = 24) Exudative AMD (n = 30)
ρ p-value ρ p-value ρ p-value
Th1 (CD4+CXCR3+IL12RB2+)a −0.53 0.002 −0.20 0.343 −0.05 0.802
Th17 (CD4+CCR6+ IL23R+)a +0.01 0.957 −0.05 0.810 +0.10 0.611
Th17/Th1 ratiob +0.69 <0.001 −0.17 0.418 −0.11 0.572
CD4+IL12RB2+a −0.15 0.420 −0.04 0.847 +0.21 0.256
CD4+IL23R+a −0.04 0.817 −0.25 0.243 +0.15 0.439
CD4+CXCR3+a −0.46 0.010 −0.17 0.426 −0.31 0.092
CD4+CCR6+a +0.14 0.476 −0.08 0.727 −0.19 0.319
CD4+CXCR3+CCR6+b −0.46 0.011 −0.25 0.246 −0.26 0.172
Table 3. Correlations between increasing age and CD4+ T-cells surface proteins are present in control 
individuals (CD4+CXCR3+, CD4+CXCR3+IL12RB2+, and CD4+CXCR3+CCR6+), but not in patients with 
non-exudative or exudative age-related macular degeneration (AMD). Abbreviations: n = number; AMD = age-
related macular degeneration; Th1 = T helper 1; Th17 = T helper 17. Correlation coefficients (ρ) and p-values 
are calculated using: aPearson’s correlation; bSpearman’s correlation. Cell populations with significant differences 
are greyed out.
Figure 2. Correlation networks of CD4+ T-cell surface proteins in control individuals, patients with non-
exudative age-related macular degeneration (AMD), and patients with exudative AMD. The relationships 
between surface proteins are calculated using Spearman’s correlation and the correlation coefficient is marked 
when ≥0.4 or ≤−0.4 using green or red lines, respectively. Differences in relationship patterns reveal that a 
complex systemic immune dysfunction may be present in patients with AMD.
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immunosenescence. T-cells produce and secrete IL-2, a cytokine that induces cell proliferation and supports 
long-term growth of T-cells. As T-cells age, they lose their ability to produce and respond to IL-2 resulting in 
impaired T-cell function38. We have previously identified increased levels of aged, i.e. CD56+CD28− T-cells in 
individuals with AMD11. In this study, we found that the frequency of Th1-cells decreased with advancing age 
in control individuals, but not in individuals with nonexudative or exudative AMD suggesting a dysfunctional 
aging of Th1 cells in patients with AMD. Accordingly, we found that the Th17/Th1 ratio increased with age 
in controls, but not in patients with AMD. Our findings in controls are supported by a previous study which 
showed that aging introduces a functional shift from Th1 to a Th2 response characterized by a reduction in the 
Th1 cytokine IFN-γ and an increase in the Th2 cytokine IL-4 and the immunoregulatory and B-cell promoting 
cytokine IL-1039.
An alternative differentiation from naïve CD4+ T-cells into Th17-cells is encouraged by TGF-β, IL-6 and to 
a lesser degree by TNF-α, IL-1β, and IL-23. Th17-cells are considered to be pro-inflammatory and have been 
implicated in autoimmune diseases and human inflammatory conditions, including multiple sclerosis40. IL-17 is 
a signature cytokine of Th17 cells, but is also secreted by γδ T-cells and innate lymphoid cells. IL-17 appears to 
play a role in AMD. Liu et al. reported that complement component C5a is increased in the circulation of AMD 
patients and that it promotes expression of the Th17 cytokines IL-17 and IL-22 by human CD4+ T-cells41. Also, an 
association between two single nucleotide polymorphisms in the IL-17 gene, rs2275913G/A and rs3748067C/T 
and AMD was reported42. IL-17 and TNF-α have been observed at higher concentrations in AMD patients and 
may be linked to a more favorable response to anti-VEGF therapy43. Altered DNA methylation of the IL17RC 
promoter has been observed in AMD patients leading to an elevated expression of its protein and messenger 
RNA in peripheral blood and affected parts of the retina and choroid44. In mice, IL-17 stimulates neovascu-
larization in a VEGF-dependent manner after laser-injury45. In another study, modulating the IL-17 gene in 
Ccl2−/−/Cx3cr1−/−/Crb1rd8 mice using an anti-inflammatory agent TSG-6 stabilized retinal lesions46. Taken 
together, these studies indicate that IL-17 may be involved in the pathogenesis of AMD by promoting retinal neo-
vascularization. In our study, there was no absolute difference in the frequency of CCR6+ IL23R+ Th17 cells when 
comparing patients with exudative and non-exudative AMD with age-matched controls. In light of our findings, 
it is important to remember that apart from Th17 cells, γδ T-cells and innate lymphoid cells are important pro-
ducers of IL-17. Indeed, Hasegawa et al. reported that γδ T-cells and THY1+ ILCs, but not Th17 cells were the 
relevant source of IL-1745. Thus, our findings suggest that the increase in IL-17 found by other groups in patients 
with AMD is not simply explained by a higher frequency of Th17-cells.
The chemokine receptor CXCR3 is a receptor for a range of chemoattractants (such as CXCL4, CXCL9, 
CXCL10, and CXCL11), facilitates entry of cells to sites of inflammation, and plays an important role in 
CXCL10-mediated inhibition of VEGF-induced angiogenesis47, 48. We have recently demonstrated a trend 
towards lower CXCR3 expression on circulating CD4+ CD69+ T cells (activated T-cells) in patients with exuda-
tive AMD compared to age-matched controls without AMD (p = 0.07)12. In this current study, we confirm the 
results from our previous study and report a lower expression of CXCR3 on CD4+ cells in patients with exudative 
AMD (p = 0.012) compared to controls without AMD. The frequency of CD4+IL12RB2+ did not differ between 
groups, and thus the reduction in CXCR3 expression on CD4+ cells may have been responsible for the observed 
difference in Th1 cells between our study groups. Interestingly, control individuals exhibit an age-related increase 
in CD4+CXCR3+, which does not occur in patients with AMD – in the exudative AMD group, there is even a 
small but insignificant trend (ρ = −0.31, p = 0.092) towards lower CD4+CXCR3+ with age. In addition, we found 
that the expression of CCR6 on CD4+ -cells is lower in patients with both non-exudative and exudative AMD 
compared to controls. The co-expression of CXCR3 and CCR6 on CD4+ T-cells was also lower in patients with 
any AMD, and the age-related decrease which we observed in controls did not occur in patients with AMD. T-cell 
subsets express CCR6, which is a receptor for the chemoattractant CCL20 (macrophage inflammatory protein 
3α)49, 50. The chemoattractant activity is among T-cells specific to Th17 and Treg cells – Th17 cells both expresses 
the receptor and its ligand and the interaction is used to regulate the migration of Th17 cells to sites of inflamma-
tion, unlike e.g. Th1 and Th2 cells which lack a similar migratory response50, 51. Thus, it is unclear which role the 
systemic decrease in CCR6+ CD4+ T-cells and decreased co-expression of CXCR3 and CCR6 CD4+ T-cells plays, 
but this warrants further investigation.
When discussing isolated differences in systemic immunological alterations, it is important to remember 
that these cells are components of a large, complex, and interacting system. Thus, we also looked at relationships 
between the T-cell populations using correlation networks. Patients with AMD differed considerably from control 
individuals, particularly in correlations regarding CCR6+ CD4+ T-cells, CXCR3+ CD4+ T-cells, and the Th17/
Th1-ratio. It is our understanding that two important messages can be derived from this. Firstly, this underscores 
that there may be a dysfunction in these immune cell populations. Future studies call for functional analyses of 
these subgroups. Secondly, the immune dysfunction in patients with AMD may be a part of a more complex 
picture of systemic immune dysfunction. When looking at the P-values in the comparisons in Table 2 and the cor-
relations in Fig. 2, it seems that the group of non-exudative AMD may have trends towards immunological altera-
tions similar to those in patients with exudative AMD albeit less pronounced. The results may also reflect disease 
heterogeneity. Clinical studies show that within 5 years 5 percent and within 15 years 15 percent of the patients 
progress from non-exudative AMD to exudative AMD1. Hence, a large number of patients with non-exudative 
AMD never develop the exudative type. This may explain, at least partly, why the immunological fingerprint of 
the non-exudative AMD illustrated as correlation networks looks as if the correlations in controls and exudative 
AMDs were put on top of each other. Future research must focus on further investigating potential immunologi-
cal differences in subtypes of non-exudative AMD.
Some limitations of this study need to be considered. Firstly, the observational nature of our study design 
does not allow us to infer any causal relationship between Th1- and Th17-cell frequency and AMD. Thus, it 
is not possible to say whether the absence of the Th1 decrement in AMD is the cause of disease or an effect of 
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disease-related medical or lifestyle factors. Since Th1 and Th17 cells cytokines are not specific to these cell types, 
it is difficult to exclude disparity between cells and their cytokines due to lack of functional analyses of cytokines, 
e.g. measurement of IFN-γ and IL-17 after stimulation. Moreover, since we did not measure frequency of other 
T cell subsets, such as Th2 and T regulatory cells, we cannot establish whether the changes observed in our study 
are restricted to specific T-cell subsets.
In conclusion, our study demonstrates a decreased frequency of CXCR3+IL12RB2+ Th1-cells in patients with 
AMD, but no such change in the frequency of CCR6+IL23R+ Th17-cells. The age-related decrement in Th1 fre-
quency observed in healthy controls is absent in patients with AMD. The percentage of CD4+ T-cells expressing 
CCR6 was significantly lower in patients with non-exudative and exudative AMD. Moreover, we are able to repro-
duce previous findings, which show that exudative AMD is associated with a lower percentage of CD4+ T-cells 
expressing CXCR3 compared to controls. Our results suggest that patients with AMD exhibit alterations in the 
normal aging processes and in the complex interplay of the adaptive immune system. Taken together, our results 
support the notion that the adaptive immune system may be implicated in the pathogenesis of AMD and that 
AMD is a disease where normal aging processes become dysregulated.
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